Table 4 Clinical and viral genomic characteristics of newly diagnosed MSM.

From: Men who have sex with men newly diagnosed with HIV-1 in Portugal (2023–2024): a comparative analysis of transmission clusters between migrants and non-migrants

 

N

Overall

Non-Migrant (N = 18)

Migranta (N = 42)

p-value1

N (%) [95% CI]

N (%) [95% CI]

N (%) [95% CI]

STI ever diagnosed

60

32 (53%) [40%, 66%]

8 (44%) [22%, 69%]

24 (57%) [41%, 72%]

0.4

Syphilisb

32

23 (72%) [53%, 86%]

7 (88%) [47%, 99%]

16 (67%) [45%, 84%]

0.4

Gonorrheab

32

13 (41%) [24%, 59%]

4 (50%) [22%, 78%]

9 (38%) [20%, 59%]

0.7

Chlamydiab

32

5 (16%) [5.9%, 34%]

2 (25%) [4.5%, 64%]

3 (13%) [3.3%, 33%]

0.6

Other STIb

32

6 (19%) [7.9%, 37%]

1 (13%) [0.66%, 53%]

5 (21%) [7.9%, 43%]

 > 0.9

Last STI diagnosis

31

 

0.7

 ≤ 12 months ago

 

12 (39%) [22%, 58%]

4 (50%) [22%, 78%]

8 (35%) [17%, 57%]

 

 > 12 months ago

19 (61%) [42%, 78%]

4 (50%) [22%, 78%]

15 (65%) [43%, 83%]

Viral load (copies/mL)

59

 

0.3

 ≤ 10,000

 

12 (20.4%) [11%, 33%]

3 (16.7%) [4.4%, 42%]

9 (22%) [11%, 38%]

 

10,000–100,000

31 (52.5%) [39%, 66%]

8 (44.4%) [22%, 69%]

23 (56%) [40%, 71%]

 ≥ 100,000

16 (27.1%) [17%, 40%]

7 (38.9%) [18%, 64%]

9 (22%) [11%, 38%]

Subtype

60

 

0.022

B

 

39 (65%) [52%, 77%]

7 (38.9%) [18%, 64%]

32 (76.2%) [60%, 87%]

 

C

8 (13.3%) [6.3%, 25%]

3 (16.7%) [4.4%, 42%]

5 (11.9%) [4.5%, 26%]

A1

4 (6.7%) [2.2%, 17%]

3 (16.1%) [4.4%, 42%]

1 (2.4%) [0.12%, 14%]

F

4 (6.7%) [2.2%, 17%]

3 (16.7%) [4.4%, 42%]

1 (2.4%) [0.12%, 14%]

G

3 (5.0%) [1.3%, 15%]

1 (5.6%) [0.29%, 29%]

2 (4.8%) [0.83%, 17%]

CRFs

2 (3.3%) [0.58%, 13%]

1 (5.6%) [0.29%, 29%]

1 (2.4%) [0.12%, 14%]

B vs Non-B

60

 

0.006

B

 

39 (65%) [52%, 77%]

7 (38.9%) [18%, 64%]

32 (76.2%) [60%, 87%]

 

Non-B

21 (35%) [23%, 48%]

11 (61.1%) [36%, 82%]

10 (23.8%) [13%, 40%]

Recent Infection

60

35 (58%) [45%, 71%]

11 (61.1%) [36%, 82%]

24 (57%) [41%, 72%]

0.8

SDRM

60

9 (15%) [7.5%, 27%]

3 (16.7%) [4.4%, 42%]

6 (14.3%) [5.9%, 29%]

 > 0.9

PI resistance

60

1 (1.7%) [0.09%, 10%]

0 (0%) [0.00%, 22%]

1 (2.4%) [0.12%, 14%]

 > 0.9

NRTI resistance

60

1 (1.7%) [0.09%, 10%]

1 (5.6%) [0.29%, 29%]

0 (0%) [0.00%, 10%]

0.3

NNRTI resistance

60

7 (12%) [5.2%, 23%]

2 (11%) [1.9%, 36%]

5 (12%) [4.5%, 26%]

 > 0.9

INSTI resistance

60

0 (0%) [0.00%, 7.5%]

0 (0%) [0.00%, 22%]

0 (0%) [0.00%, 10%]

 

SDRM

K103N

60

6 (10%) [4.1%, 21%]

1 (5.6%) [0.29%, 29%]

5 (12%) [4.5%, 26%]

0.7

M41L

60

1 (1.7%) [0.09%, 10%]

1 (5.6%) [0.29%, 29%]

0 (0%) [0.00%, 10%]

 

T215D

60

1 (1.7%) [0.09%, 10%]

1 (5.6%) [0.29%, 29%]

0 (0%) [0.00%, 10%]

 

L100I

60

1 (1.7%) [0.09%, 10%]

1 (5.6%) [0.29%, 29%]

0 (0%) [0.00%, 10%]

 

L23I

60

1 (1.7%) [0.09%, 10%]

0 (0%) [0.00%, 22%]

1 (2.4%) [0.12%, 14%]

 
  1. CI, Confidence Interval; STI, Sexual Transmitted Infection; SDRM - Surveillance Drug-Resistance Mutation; PI - Protease Inhibitor; NRTI - Nucleoside Reverse Transcriptase Inhibitor; NNRTI - Non-Nucleoside Reverse Transcriptase Inhibitor; INSTI - Integrase Stand Transfer Inhibitor; The bold p-values ≤ 0.05.
  2. 1 Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test.
  3. a Place of birth other than Portugal.
  4. b Ever.
  5. c Branch support 90%.
Back to article page